Evidence map›Paper›PMID 40109248›Full record

ReviewCardiology journal2025

Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction - 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators' viewpoint.

Jacek Kubica, Piotr Adamski, Jolita Badariene, Marc Bonaca, Piotr Buszman, Rahima Gabulova, Robert Gajda, Tobias Geisler, Robert Gil, Diana A Gorog and 22 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Jacek KubicaDepartment of Cardiology and Internal Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Piotr AdamskiDepartment of Cardiology and Internal Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Jolita BadarieneFaculty of Medicine, Vilnius University, Vilnius, Lithuania.
Marc BonacaCPC Clinical Research, Aurora, United States.
Piotr BuszmanCardiology Department, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland; Center for Cardiology and Cardiac Surgery of American Heart of Poland, Bielsko-Biała, Poland.
Rahima GabulovaTeaching-Therapeutical Hospital, Azerbaijan Medical University, Baku, Azerbaijan.
Robert GajdaGajda-Med District Hospital in Pultusk, Poland.
Tobias GeislerMedical Clinic III, University Hospital Tübingen, Tübingen, Germany.
Robert GilDepartment of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland.
Diana A GorogPostgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom.
Paul A GurbelSinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, United States.
Tomasz HajdukiewiczDepartment of Cardiology, Provincial Hospital, Elblag, Poland.
Bartosz HudzikDepartment of Metabolic Disease Prevention, Faculty of Public Health in Bytom, Medical University of Silesia, Bytom, Poland.
Stefan JamesDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Young-Hoon JeongCAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Republic of Korea.
Adam KernDepartment of Cardiology and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, Poland.
Wacław KochmanThe National Institute of Cardiology, Department of Cardiology, Bielanski Hospital, Warsaw, Poland.
Aldona KubicaDepartment of Cardiac Rehabilitation and Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Wiktor KuliczkowskiInstitute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Przemysław MagielskiInterventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland.
Piotr NiezgodaDepartment of Cardiology and Internal Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland. piotr.niezgoda1986@gmail.com.ORCID 0000-0002-9912-9730
Małgorzata OstrowskaDepartment of Cardiology and Internal Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Paolo RaggiDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Uzeyir RahimovDepartment of Cardiology, Baku Medical Plaza, Baku, Azerbaijan.
Grzegorz SkoniecznyDepartment of Cardiology and Intensive Cardiological Care, Rydygier Provincial Hospital, Torun, Poland.
Jolanta M Siller-MatulaDepartment of Cardiology, Medical University of Vienna, Vienna, Austria.
Giuseppe SpecchiaDepartment of Cardiology, Policlinico di Monza, Monza, Italy.
Łukasz SzarpakDepartment of Clinical Research and Development, LUXMED Group, Warsaw, Poland.
Paweł SzymańskiDepartment of Cardiology, Interventional Cardiology and Electrophysiology with Cardiac Intensive Care Unit, Tertiary Care Hospital in Grudziadz, Poland.
Udaya TantrySinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, United States.
Julia UmińskaDepartment of Cardiology and Internal Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Eliano Pio NavareseClinical and Interventional Cardiology, Sassari University Hospital, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B). However, the available scientific evidence justifies a personalized approach differentiating the indications for pre-treatment with oral P2Y12 receptor inhibitors depending on the concomitant administration of opioids. In our opinion, in patients undergoing primary PCI not treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be applied, while in patients undergoing primary PCI treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be considered.

Indexed as

Percutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Guidelines as TopicPrecision MedicinePurinergic P2Y Receptor AntagonistsST Elevation Myocardial InfarctionHumansTreatment OutcomePlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsACSESC guidelinesP2Y12pretreatmentSTEMI

Identifiers

PMID40109248
PMCPMC12068194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.